Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.975 USD | -2.63% | -14.16% | +196.30% |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Apr. 11 | Top Midday Gainers | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | 277.8 | 97.5 | 74.45 |
Enterprise Value (EV) 1 | 116.4 | -25.58 | -32 |
P/E ratio | -2.46 x | -2.13 x | -2.07 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | - | - | - |
EV / FCF | -4,599,176 x | 1,247,483 x | -9,244,691 x |
FCF Yield | -0% | 0% | -0% |
Price to Book | 1.64 x | 0.76 x | 0.7 x |
Nbr of stocks (in thousands) | 26,554 | 26,568 | 27,573 |
Reference price 2 | 10.46 | 3.670 | 2.700 |
Announcement Date | 3/7/22 | 3/6/23 | 3/28/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | -4.696 | -11.77 | -35.67 | -45.14 | -21.47 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.547 | -20.67 | -47.48 | -45.24 | -35.12 |
Net income 1 | -6.547 | -20.67 | -47.48 | -45.24 | -35.12 |
Net margin | - | - | - | - | - |
EPS 2 | -4.450 | -10.49 | -4.244 | -1.720 | -1.301 |
Free Cash Flow | - | -6.57 | -25.3 | -20.51 | 3.462 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 6/21/21 | 6/21/21 | 3/7/22 | 3/6/23 | 3/28/24 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -9.383 | -10.7 | -13.13 | -13.7 | -8.748 | -9.554 | -23.44 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -9.615 | -10.54 | -13.2 | -14.6 | -9.682 | -7.762 | -22.29 |
Net income 1 | -10.94 | -10.54 | -13.2 | -14.6 | -9.682 | -7.762 | -22.29 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -0.7000 | 1.250 | -0.5000 | -0.5600 | -0.3700 | -0.2900 | -0.8400 |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 11/8/21 | 3/7/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/6/23 | 5/11/23 |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | 21.2 | 20.5 | 161 | 123 | 106 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | -6.57 | -25.3 | -20.5 | 3.46 |
ROE (net income / shareholders' equity) | - | -96.7% | -50.2% | -30.6% | -29.7% |
ROA (Net income/ Total Assets) | - | -32% | -22.5% | -18.3% | -10.9% |
Assets 1 | - | 64.67 | 210.7 | 247.2 | 321.3 |
Book Value Per Share 2 | -3.350 | -7.310 | 6.370 | 4.840 | 3.880 |
Cash Flow per Share 2 | 12.80 | 5.990 | 1.790 | 1.640 | 3.360 |
Capex | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 6/21/21 | 6/21/21 | 3/7/22 | 3/6/23 | 3/28/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+203.33% | 230M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.64% | 21.25B | |
-5.94% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- ELYM Stock
- Financials Eliem Therapeutics, Inc.